Serina Therapeutics Files 8-K, Reports Material Agreement

Ticker: SER · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1708599

Serina Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySerina Therapeutics, Inc. (SER)
Form Type8-K
Filed DateApr 29, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, company-name-change, financial-statements

TL;DR

Serina Therapeutics signed a big deal, filed financials, and used to be AgeX.

AI Summary

On April 25, 2025, Serina Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc. until June 6, 2017.

Why It Matters

This filing indicates a significant new agreement for Serina Therapeutics, which could impact its future operations and financial performance. Investors should monitor subsequent filings for details on this agreement.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications for the company, but specific details are not yet fully disclosed.

Key Players & Entities

  • Serina Therapeutics, Inc. (company) — Registrant
  • April 25, 2025 (date) — Date of earliest event reported
  • AgeX Therapeutics, Inc. (company) — Former company name
  • June 6, 2017 (date) — Date of name change
  • 601 Genome Way, Suite 2001, Huntsville, Alabama 35806 (location) — Principal executive offices address

FAQ

What is the nature of the material definitive agreement Serina Therapeutics entered into?

The filing states that Serina Therapeutics, Inc. entered into a material definitive agreement on April 25, 2025, but the specific details of this agreement are not provided in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on April 25, 2025.

What was Serina Therapeutics, Inc. formerly known as?

Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.

On what date did the company change its name from AgeX Therapeutics, Inc.?

The company changed its name from AgeX Therapeutics, Inc. on June 6, 2017.

Where are Serina Therapeutics, Inc.'s principal executive offices located?

Serina Therapeutics, Inc.'s principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Serina Therapeutics, Inc. (SER).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.